Hologic, Inc. (HOLX)
Largest Insider Buys in Sector
HOLX Stock Price History Chart
HOLX Stock Performance
About Hologic, Inc.
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion …
Insider Activity of Hologic, Inc.
Over the last 12 months, insiders at Hologic, Inc. have bought $0 and sold $18.21M worth of Hologic, Inc. stock.
On average, over the past 5 years, insiders at Hologic, Inc. have bought $0 and sold $16.83M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 26,000 shares for transaction amount of $1.01M was made by Dockendorff Charles J (director) on 2018‑03‑15.
List of Insider Buy and Sell Transactions, Hologic, Inc.
| 2024-08-29 | Sale | Chief Financial Officer | 52,679 0.0226% | $80.56 | $4.24M | +0.28% | ||
| 2024-08-06 | Sale | Div. President, GYN Surgical | 476 0.0002% | $83.11 | $39,559 | -1.89% | ||
| 2024-08-01 | Sale | Principal Accounting Officer | 5,093 0.0022% | $81.99 | $417,570 | -2.66% | ||
| 2024-07-30 | Sale | Chairman, President and CEO | 44,039 0.0187% | $81.70 | $3.6M | +1.84% | ||
| 2024-07-17 | Sale | Chairman, President and CEO | 3,672 0.0016% | $80.13 | $294,223 | +2.48% | ||
| 2024-07-17 | Sale | director | 9,039 0.0039% | $79.50 | $718,601 | +2.48% | ||
| 2024-03-14 | Sale | director | 16,441 0.0069% | $75.50 | $1.24M | +3.45% | ||
| 2024-03-08 | Sale | director | 9,039 0.0038% | $76.40 | $690,607 | +0.96% | ||
| 2024-03-08 | Sale | director | 1,465 0.0006% | $76.21 | $111,648 | +0.96% | ||
| 2024-01-29 | Sale | Chief Financial Officer | 14,940 0.0064% | $75.00 | $1.12M | +1.82% | ||
| 2024-01-02 | Sale | director | 16,017 0.0067% | $72.00 | $1.15M | +5.40% | ||
| 2023-12-11 | Sale | director | 10,000 0.0042% | $68.71 | $687,116 | +10.47% | ||
| 2023-11-29 | Sale | Chairman, President and CEO | 47,711 0.0198% | $70.41 | $3.36M | +7.24% | ||
| 2023-11-21 | Sale | Div. President, GYN Surgical | 7,500 0.0031% | $71.85 | $538,890 | +5.06% | ||
| 2023-06-15 | Sale | director | 10,000 0.004% | $79.72 | $797,240 | -8.53% | ||
| 2023-05-05 | Sale | Div. President, GYN Surgical | 2,390 0.001% | $83.73 | $200,115 | -10.65% | ||
| 2023-02-07 | Sale | Principal Accounting Officer | 9,128 0.0036% | $85.28 | $778,445 | -11.80% | ||
| 2022-12-14 | Sale | SVP, Human Resources | 1,649 0.0007% | $76.40 | $125,984 | +3.41% | ||
| 2022-11-30 | Sale | Chairman, President and CEO | 33,500 0.0135% | $75.65 | $2.53M | +3.04% | ||
| 2022-11-15 | Sale | Group Pres, Global Diagnostics | 12,490 0.0051% | $75.30 | $940,509 | +5.18% |
Insider Historical Profitability
| MACMILLAN STEPHEN P | Chairman, President and CEO | 1157562 0.4984% | $78.62 | 4 | 9 | +18.31% |
| Dockendorff Charles J | director | 1572 0.0007% | $78.62 | 1 | 2 | +5.07% |
| MUIR GLENN P | Executive VP and CFO | 815306 0.351% | $78.62 | 1 | 55 | <0.0001% |
| CASCELLA ROBERT | CEO and President | 400655 0.1725% | $78.62 | 1 | 18 | <0.0001% |
| CUMMING JOHN W | Chairman | 305975 0.1317% | $78.62 | 1 | 16 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $2.09B | 11.48 | 26.79M | -3.2% | -$69.11M | 0.04 | |
| BlackRock | $1.82B | 10.02 | 23.39M | -3.58% | -$67.82M | 0.04 | |
| T Rowe Price Investment Management Inc | $1.74B | 9.58 | 22.35M | +1.28% | +$22.05M | 1.07 | |
| State Street | $816.57M | 4.49 | 10.47M | -5.67% | -$49.11M | 0.03 | |
| T. Rowe Price | $490.93M | 2.7 | 6.3M | +77.68% | +$214.63M | 0.06 |